Gene therapy for ovarian cancer: Progress and potential

Hematology/Oncology Clinics of North America

Volumn 17, Issue 4, 2003, Pages 1021-1050

  Kirby, Tyler O ^a   Curiel, David T ^b   Alvarez, Ronald D ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BRCA1 PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ONYX 015; PROTEIN KINASE C ALPHA; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; TOPOTECAN;

ADENO ASSOCIATED VIRUS; CANCER CELL; DNA VECTOR; FEMALE; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

EID: 0042934212     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00055-8     Document Type: Review

References (178)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49(1):8-31.
2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275(5304):1320-3.
3. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73(2):309-19.
4. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997;15(8):953-60.
5. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74(6):957-67.
6. Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung MC. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene 1997;14(16):1965-71.
7. Coukos G, Rubin SC. Gene therapy for ovarian cancer. Oncology (Huntingt) 2001;15(9): 1197-204.
8. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995;92(5): 1401-5.
9. Carter BJ. Adeno-associated virus and adeno-associated virus vectors for gene delivery. In: Templeton NS, Lasic DD, editors. Gene therapy: therapeutic mechanisms and strategies. New York: Marcel Dekker; 2000. p. 41-59.
10. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001;412(6850):914-7.
11. Vermeij J, Zeinoun Z, Neyns B, Teugels E, Bourgain C, De Greve J. Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. Br J Cancer 2001;85(10):1592-9.
12. Meyer F, Finer M. Gene therapy: progress and challenges. Cell Mol Biol [Noisy-le-grand] 2001;47(8):1277-94.
13. Pizzato M, Blair ED, Fling M, Kopf J, Tomassetti A, Weiss RA, et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther 2001;8(14):1088-96.
14. Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999;5(7):1708-14.
15. Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 1997;3(11):1959-68.
16. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A 1993;90(10):4645-9.
17. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Ther 1995;2(10):710-22.
18. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, et al. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther 1998;5(11):1538-44.
19. Anderson WF. Human gene therapy. Nature 1998;392(6679 Suppl):25-30.
20. Shangguan T, Cabral-Lilly D, Purandare U, Godin N, Ahl P, Janoff A, et al. A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine-condensed plasmid DNA. Gene Ther 2000;7(9):769-83.
21. Lee MJ, Cho SS, You JR, Lee Y, Kang BD, Choi JS, et al. Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model. Gene Ther 2002;9(13):859-66.
22. Kim CK, Haider Kh H, Choi SH, Choi EJ, Ahn WS, Kim YB. Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells. Gynecol Oncol 2002;84(1):85-93.
23. Tousignant JD, Gates AL, Ingram LA, Johnson CL, Nietupski JB, Cheng SH, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum Gene Ther 2000;11(18):2493-513.
24. Mandell RB, Mandell LZ, Link Jr CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59(3):661-8.
25. Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1995;1(12):1571-80.
26. Rosenfeld ME, Wang M, Siegal GP, Alvarez RD, Mikheeva G, Krasnykh V, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996;74(8):455-62.
27. Behbakht K, Benjamin I, Chiu HC, Eck SL, Van Deerlin PG, Rubin SC, et al. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am J Obstet Gynecol 1996;175(5): 1260-5.
28. Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 1996;61(2):175-9.
29. Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum LB, et al. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res 1997;17(2A):811-3.
30. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3(1):85-92.
31. Pitts JD. Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol Carcinog 1994;11(3):127-30.
32. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996;56(12):2697-702.
33. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53(21):5274-83.
34. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997;349(9044):2-3.
35. Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 1997;4(2):91-6.
36. Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996;3(6):373-84.
37. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol 1996;24(7):829-38.
38. Nagy HJ, Panis Y, Fabre M, Engelmann C, Soubrane O, Houssin D, et al. Efficient suicide gene therapy of transduced and distant untransduced ovary tumors is correlated with significant increase of intratumoral T and NK cells. Biomed Pharmacother 2000;54(10):479-86.
39. Rancourt C, Robertson 3rd MW, Wang M, Goldman CK, Kelly JF, Alvarez RD, et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res 1998;4(2):265-70.
40. McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998;5(8):1061-9.
41. Bentires-Alj M, Hellin AC, Lechanteur C, Princen F, Lopez M, Fillet G, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther 2000;7(1):20-6.
42. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000;7(20):1738-43.
43. Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther 2000;7(10):1348-56.
44. Tong XW, Kieback DG, Ramesh R, Freeman SM. Molecular aspects of ovarian cancer: is gene therapy the solution? Hematol Oncol Clin N Am 1999;13(1):109-33.
45. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001;14(3):165-71.
46. Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Gynecol Oncol 2002;84(2):210-5.
47. Kigawa J, Terakawa N. Adenovirus-mediated transfer of a p53 gene in ovarian cancer. Adv Exp Med Biol 2000;465:207-14.
48. Song K, Cowan KH, Sinha BK. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res 1999;11(3):153-9.
49. Wolf JK, Mills GB, Bazzet L, Bast Jr RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 1999;75(2):261-6.
50. Kim J, Hwang ES, Kim JS, You EH, Lee SH, Lee JH. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther 1999;6(2):172-8.
51. Xie Y, Gilbert JD, Kim JH, Freytag SO. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res 1999;5(12):4224-32.
52. Zang RY, Shi DR, Lu HJ, Cai SM, Lu DR, Zhang YJ, et al. Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo. Int J Gynecol Cancer 2001;11(1): 18-23.
53. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6(1):250-9.
54. Holt JT. Breast cancer genes: therapeutic strategies. Ann N Y Acad Sci 1997;833:34-41.
55. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96(5):2110-5.
56. Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 1999;59(24):6063-7.
57. Wolf JK, Kim TE, Fightmaster D, Bodurka D, Gershenson DM, Mills G, et al. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 1999;73(1):27-34.
58. Marchini S, Codegoni AM, Bonazzi C, Chiari S, Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer 1997;76(2): 146-9.
59. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 1997;74(2):148-55.
60. Lin J, Page C, Jin X, Sethi AO, Patel R, Nunez G. Suppression activity of pro-apoptotic gene products in cancer cells, a potential application for cancer gene therapy. Anticancer Res 2001;21(2A):831-9.
61. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95(9): 4997-5002.
62. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88(2):386-401.
63. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998;16(8):2583-90.
64. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996;93(24):14094-9.
65. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999;59(9):2121-6.
66. Tsuruta Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yura Y, et al. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer 2001;37(4):531-41.
67. Helm CW, Shrestha K, Thomas S, Shingleton HM, Miller DM. A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol 1993;49(3):339-43.
68. Durland RH, Kessler DJ, Gunnell S, Duvic M, Pettitt BM, Hogan ME. Binding of triple helix forming oligonucleotides to sites in gene promoters. Biochemistry 1991;30(38):9246-55.
69. Ebbinghaus SW, Gee JE, Rodu B, Mayfield CA, Sanders G, Miller DM. Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 1993;92(5):2433-9.
70. Mayfield C, Ebbinghaus S, Gee J, Jones D, Rodu B, Squibb M, et al. Triplex formation by the human Ha-ras promoter inhibits Spl binding and in vitro transcription. J Biol Chem 1994;269(27):18232-8.
71. Fei R, Shaoyang L. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line. Gynecol Oncol 2002;85(1):40-4.
72. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991;51(6): 1744-8.
73. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 1991;10(5):1111-8.
74. Wickstrom E, Bacon TA, Wickstrom EL. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 1992;52(24):6741-5.
75. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci U S A 1991;88(6):2351-5.
76. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 1992;89(24):11823-7.
77. Neuenschwander S, Roberts Jr. CT, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995;136(10):4298-303.
78. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991;253(5019):562-5.
79. Huh WK, Barnes MN, Kelley FJ, Alvarez RD. Gene therapy. Cancer Treat Res 2002;107:133-57.
80. Arafat WO, Gomez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 2002;9(4):256-62.
81. Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 1996;3(2): 89-98.
82. Irie A, Anderegg B, Kashani-Sabet M, Ohkawa T, Suzuki T, Halks-Miller M, et al. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev 1999;9(4):341-9.
83. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther 2000;7(23): 2041-50.
84. Funato T. [Circumventing multidrug resistance in human cancer by anti-ribozyme.] Nippon Rinsho 1997;55(5):1116-21.
85. Bi F, Zhang X, Fan D. [In vitro cleavage action of c-erbB-2 oncogene-specific ribozyme.] Zhonghua Zhong Liu Za Zhi 1999;21(1):7-9.
86. Bi F, Fan D, Hui H, Wang C, Zhang X. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme. Cancer Gene Ther 2001;8(11): 835-42.
87. Wiechen K, Zimmer C, Dietel M. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther 1998;5(1): 45-51.
88. Sullenger BA, Milich L. Gene therapy applications of ribozymes. In: Templeton NS, Lasic DD, editors. Gene therapy: therapeutic mechanisms and strategies. New York: Marcel Dekker; 2000. p. 291-304.
89. Lui VW, He Y, Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol Ther 2001;3(2):169-77.
90. Redemann N, Holzmann B, von Ruden T, Wagner EF, Schlessinger J, Ullrich A. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12(2):491-8.
91. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A 1994;91(6): 2181-5.
92. Ueno H, Colbert H, Escobedo JA, Williams LT. Inhibition of PDGF beta receptor signal transduction by coexpression of a truncated receptor. Science 1991;252(5007):844-8.
93. Mercola M, Deininger PL, Shamah SM, Porter J, Wang CY, Stiles CD. Dominant-negative mutants of a platelet-derived growth factor gene. Genes Dev 1990;4(12B):2333-41.
94. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54(24):6504-11.
95. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996;93(16):8502-7.
96. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56(7): 1615-20.
97. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3(4): 437-42.
98. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001;7(7): 2057-66.
99. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 2000;97(9):4802-7.
100. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 2000;7(12):1027-33.
101. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998;9(6): 823-33.
102. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60(8):2169-77.
103. Saga Y, Mizukami H, Suzuki M, Urabe M, Kume A, Nakamura T, et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 2001;8(19):1450-5.
104. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995;92(18):8522-6.
105. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996;3(1):11-7.
106. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997;57(7):1335-43.
107. Zhang JF, Hu C, Geng Y, Selm J, Klein SB, Orazi A, et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci U S A 1996;93(9):4513-8.
108. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL. Tumour therapy in mice using adenovirus vectors expressing human TNFα. Int J Oncol 1998;12(3):509-15.
109. Wright P, Zheng C, Moyana T, Xiang J. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression. Cancer Gene Ther 1998;5(6):371-9.
110. Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P, et al. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther 1998;5(7):965-74.
111. D'Incan C, Sanches R, Kuiper M, Penault-Llorca F, De Latour M, Monceau S, et al. Gamma-interferon gene transfer as a therapeutic strategy for ovarian cancer. Adv Exp Med Biol 1998;451:349-52.
112. Klimp AH, van der Vaart E, Lansink PO, Withoff S, de Vries EG, Scherphof GL, et al. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther 2001;8(4):300-7.
113. Morse MA, Lyerly HK. DNA and RNA modified dendritic cell vaccines. World J Surg 2002;26(7):819-25.
114. Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994;1(2):88-98.
115. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993;151(11):6577-82.
116. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobutin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90(2):720-4.
117. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165(10): 5713-9.
118. Rudginsky S, Siders W, Ingram L, Marshall J, Scheule R, Kaplan J. Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol Ther 2001;4(4):347-55.
119. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257(5066):99-103.
120. Bienzle D, Abrams-Ogg AC, Kruth SA, Ackland-Snow J, Carter RF, Dick JE, et al. Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. Proc Natl Acad Sci U S A 1994;91(1):350-4.
121. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16(1):165-72.
122. Ward M, Pioli P, Ayello J, Reiss R, Urzi G, Richardson C, et al. Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Clin Cancer Res 1996;2(5):873-6.
123. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Gonzalez-Garcia M, et al. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci U S A 1995;92(24):11024-8.
124. Robertson 3rd MW, Barnes MN, Rancourt C, Wang M, Grim J, Alvarez RD, et al. Gene therapy for ovarian carcinoma. Semin Oncol 1998;25(3):397-406.
125. Kim M, Wright M, Deshane J, Accavitti MA, Tilden A, Saleh M, et al. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Hum Gene Ther 1997;8(2):157-70.
126. Kirn DH. Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J Clin Invest 2000;105(7):837-9.
127. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996;70(4):2296-306.
128. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11. 6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996;220(1):152-62.
129. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19(1):2-12.
130. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62(20):5736-42.
131. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6(10):1134-9.
132. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7(22):1925-9.
133. Ganly I, Kim YT, Hann B, Balmain A, Brown R. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther 2001;8(5):369-75.
134. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000;60(15):4167-74.
135. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000;6(8):3342-53.
136. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000;7(2):275-83.
137. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62(16):4656-62.
138. Link Jr CJ, Moorman D, Seregina T, Levy JP, Schabold KJ. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996;7(9):1161-79.
139. Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Kaufman RH, Ramzy I, et al. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J Soc Gynecol Invest 2002;9(3):174-80.
140. Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Orlowska-Volk M, et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer 2002;12(1):66-73.
141. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000;7(6):839-44.
142. Hasenburg A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001;83(3):549-54.
143. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000;2(5):524-30.
144. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19(14):3422-33.
145. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000;6(8):3081-7.
146. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9(7):553-66.
147. Tait DL, Obermiller PS, Holt JT. Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy. Gynecol Oncol 2000;79(3):471-6.
148. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999;5(11):3357-63.
149. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20(6):1562-9.
150. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 1996;93(26):15346-51.
151. Bauknecht T, Meinhold-Heerlein I. Gene therapy of ovarian cancer. Curr Womens Health Rep 2002;2(1):39-46.
152. Tong X, Engehausen DG, Freund CT, Agoulnik I, Guo Z, Oehler MK, et al. The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. Anticancer Res 1998;18(2A):719-25.
153. Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther 1999;6(2):99-106.
154. Vandier D, Calvez V, Massade L, Gouyette A, Mickley L, Fojo T, et al. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst 2000;92(8):642-7.
155. Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001;7(8):2496-504.
156. Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001;61(4):1291-5.
157. Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol 2002;84(2):228-34.
158. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, et al. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 2002;85(3):451-8.
159. Szary J, Kalita K, Przybyszewska M, Dus D, Kieda C, Janik P, et al. KDR promoter can transcriptionally target cytosine deaminase suicide gene to cancer cells of nonendothelial origin. Anticancer Res 2001;21(5):3471-5.
160. Friedman EL, Hayes DF, Kufe DW. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res 1986;46(10): 5189-94.
161. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8(1):275-80.
162. Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 2000;6(11):4323-33.
163. Szpak CA, Soper JT, Thor A, Schlom J, Johnston WW. Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. Acta Cytol 1989;33(2): 205-14.
164. Lastoria S, D'Amico P, Mansi L, Giordano GG, Rossiello R, Schlom J, et al. A prospective imaging study of 131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report. Nucl Med Commun 1988;9(5):347-56.
165. Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piche A, Pierce GF, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998;4(10):2455-61.
166. Vanderkwaak TJ, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999;74(2):227-34.
167. Khuu H, et al. Detection of Coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation. Appl Immunohistochem Mol Morphol 1999;7:266-70.
168. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M, et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 2002;9(16):1093-100.
169. Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA, et al. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther 2000;11(12):1657-69.
170. Barnes MN, Pustilnik TB. Current strategies in gene therapy for ovarian cancer. Curr Opin Obstet Gynecol 2001;13(1):47-51.
171. Schellingerhout D, Bogdanov Jr A, Marecos E, Spear M, Breakefield X, Weissleder R. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998;9(11):1543-9.
172. Zinn KR, Chaudhuri TR. Imaging adenovirus-mediated gene transfer. In: Douglas JT, editor. Adenoviral vectors for gene therapy. Birmingham, AL: Ancademic Press; 2002. p. 655-77.
173. Zinn KR, Buchsbaum DJ, Chaudhuri TR, Mountz JM, Grizzle WE, Rogers BE. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radio-labeled with 99mTc or 188Re. J Nucl Med 2000;41(5):887-95.
174. Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nucl Med Biol 2000;28(2):135-44.
175. Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Detection and measurement of in vitro gene transfer by gamma camera imaging. Gene Ther 2001;8(4):291-9.
176. Zinn KR, Chaudhuri TR, Krasnykh VN, Buchsbaum DJ, Belousova N, Grizzle WE, et al. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 2002;223(2):417-25.
177. Zinn KR, Chaudhuri TR. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med Mol Imaging 2002;29(3):388-99.
178. MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Toyokuni T, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999;6(5):785-91.